menu
    • menu
    [{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Genialis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Inhibrx \/ Genialis","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Genialis"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"INBRX-109","moa":"DR5","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"Alpha-1 antitrypsin protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"INBRX-109","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Actinium-225 Conjugated Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Inhibrx","highestDevelopmentStatusID":"4","companyTruncated":"Inhibrx \/ Inhibrx"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"rhAAT-Fc","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"INBRX-101","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Demerger","leadProduct":"INBRX-105","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Inhibrx","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"INBRX-109","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Inhibrx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Inhibrx \/ Not Applicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"SAR447537","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals by Inhibrx

    Menu

    Inhibrx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SAR447537

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $2,196.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Sanofi Completes Acquisition of Inhibrx, Inc.

                            Details : Sanofi will acquire all the assets and liabilities associated with INBRX-101, a recombinant alpha-1 antitrypsin augmentation therapy currently in a trial for alpha-1 antitrypsin deficiency.

                            Product Name : INBRX-101

                            Product Type : Large molecule

                            Upfront Cash : $2,196.0 million

                            May 30, 2024

                            Lead Product(s) : SAR447537

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $2,196.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INBRX-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $2,196.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Inhibrx Announces Sale of INBRX-101 to Sanofi for an Aggregate Value of up to $2.2 B

                            Details : Sanofi will acquire assets and liabilities of INBRX-101, a recombinant alpha-1 antitrypsin augmentation therapy in a registrational trial for alpha-1 antitrypsin deficiency.

                            Product Name : INBRX-101

                            Product Type : Large molecule

                            Upfront Cash : $2,196.0 million

                            January 22, 2024

                            Lead Product(s) : INBRX-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $2,196.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INBRX-105,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Sanofi

                            Deal Size : $200.0 million

                            Deal Type : Demerger

                            DEALS_DEV arrow-down

                            Inhibrx Announces Sale of INBRX-101 to Sanofi for an Aggregate Value of up to $2.2 B

                            Details : Under the agreement, non-101 assets, like INBRX-105, INBRX-106, and INBRX-109, will be spun out into a new publicly traded company, Inhibrx Biosciences, separate from the original Company.

                            Product Name : INBRX-105

                            Product Type : Large molecule

                            Upfront Cash : $200.0 million

                            January 22, 2024

                            Lead Product(s) : INBRX-105,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Sanofi

                            Deal Size : $200.0 million

                            Deal Type : Demerger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INBRX-109,Temozolomide,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

                            Details : INBRX-109 is a precision-engineered, tetravalent death receptor 5 (DR5) agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation, which is investigated for Ewing sarcoma.

                            Product Name : INBRX-109

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 02, 2023

                            Lead Product(s) : INBRX-109,Temozolomide,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INBRX-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

                            Details : INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein designed to safely achieve and maintain levels of Alpha-1 Antitrypsin Deficiency and received Fast Track Designation.

                            Product Name : INBRX-101

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 30, 2023

                            Lead Product(s) : INBRX-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhAAT-Fc

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Ho...

                            Details : INBRX-101 is a precisely engineered recombinant human AAT-Fc fusion protein designed to safely achieve and maintain levels of alpha-1 antitrypsin (AAT) in patients with emphysema due to alpha-1 antitrypsin deficiency (AATD).

                            Product Name : INBRX-101

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 26, 2023

                            Lead Product(s) : rhAAT-Fc

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Actinium-225 Conjugated Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NorthStar Medical Radioisotopes and Inhibrx Enter into Collaboration Agreement for the Development and Product...

                            Details : Under this agreement with Inhibrx, NorthStar will support the development of a prespecified number of Inhibrx’s novel biologic products by providing the Ac-225 supply for the Actinium-225 Conjugated Therapy and access to its integrated radiopharmaceuti...

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 04, 2023

                            Lead Product(s) : Actinium-225 Conjugated Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : NorthStar Medical Radioisotopes

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : INBRX-109

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inhibrx Announces Updated Efficacy and Safety Data from the Expansion Cohorts in the Phase 1 Trial of INBRX-10...

                            Details : INBRX-109 is a precision-engineered, tetravalent DR5 agonist antibody designed to exploit the tumor-biased cell death induced by DR5 activation being developed for the treatment of patients with unresectable or metastatic conventional chondrosarcoma and ...

                            Product Name : INBRX-109

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 16, 2022

                            Lead Product(s) : INBRX-109

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhAAT-Fc

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in...

                            Details : INBRX-101 is precisely engineered recombinant human AAT-Fc fusion protein designed to safely achieve and maintain levels of alpha-1 antitrypsin found in healthy individuals with dosing interval compared to weekly infusion interval plasma-derived AAT ther...

                            Product Name : INBRX-101

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : rhAAT-Fc

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Inhibrx

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rhAAT-Fc

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Inhibrx To Host Webcast to Announce Regulatory Pathway for INBRX-101, its Optimized Recombinant Human AAT-Fc P...

                            Details : INBRX-101 (rhAAT-Fc) is precisely engineered fusion protein designed to safely achieve and maintain levels of alpha-1 antitrypsin, or AAT, found healthy individuals with less frequent dosing interval compared weekly infusion interval of available plasma-...

                            Product Name : INBRX-101

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 03, 2022

                            Lead Product(s) : rhAAT-Fc

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth